Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14877043 | 0.90 | CYP3A4 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2CYP1A2 | |
| SCHEMBL20531233 | 0.90 | CYP3A4 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2CYP1A2 | |
| SCHEMBL2191494 | 0.89 | SMN1; SMN2 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2PSMB5 | |
| SCHEMBL30440112 | 0.81 | MEN1 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2PSMB5 | |
| SCHEMBL30439364 | 0.79 | CTSK (0.45) | CYP3A4TSHR | |
| SCHEMBL2188854 | 0.76 | — | — | |
| SCHEMBL13374068 | 0.75 | SMYD2 (0.42) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL16321226 | 0.74 | CYP3A4 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2190800 | 0.73 | SMYD2 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2193569 | 0.73 | CYP3A4 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288551-B2 | Targeted nitroxide agents | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110172214-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-07-14 | — | — | US | disclosed |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172214-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | TXNRD2, TXN2, HSPE1 | CYP3A4 2111/4885HTT 2621/4885SMN1; SMN2 938/4885 |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | CYP3A4 1585/4885HTT 1855/4885SMN1; SMN2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.